Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

THNR

Amplify Weight Loss Drug & Treatment ETF

Apr 29 • 04:00PM ET

23.59

-0.32 -1.34 %

Financial • Exchange Traded Fund • USA • NYSE

Category	Global or ExUS Equities - Industry Sector	Asset Type	Equities (Stocks)	Tags	Global	Return% 1Y	14.47%	Total Holdings	22	Perf Week	-3.59%
Sponsor	Amplify Investments	ETF Type		Tags	equity	Return% 3Y	-	AUM	4.06M	Perf Month	-1.05%
Fund Family		Bond Type		Tags	healthcare	Return% 5Y	-	NAV/sh		Perf Quarter	-9.70%
Index	VettaFi Weight Loss Drug & Treatment Ind...	Average Maturity		Tags	pharmaceutical	Return% 10Y		52W High	27.28 -13.54%	Perf Half Y	1.89%
Index Weighting		Commodity Type		Tags	-	Return% SI		52W Low	20.98 12.43%	Perf YTD	-6.47%
Active/Passive		Quant Type		Tags	-	Flows% 1M	0.00%	Volatility	0.42% 0.66%	Perf Year	7.99%
Dividend TTM	0.41 (1.75%)	ESG Type		Tags	-	Flows% 3M	14.27%	ATR (14)	0.29	Perf 3Y	-
Dividend Ex-Date	Dec 30, 2025	Dividend Type		Sector/Theme		Flows% YTD	61.64%	RSI (14)	34.18	Perf 5Y	-
Dividend Gr. 3/5Y	- -	Structure Type		Region		Flows% 1Y		Beta	0.37	Perf 10Y	-
Expense	0.59%	Growth/Value		SMA20	-4.16%	Flows% 3Y		Rel Volume	0.22	Prev Close	23.91
Inverse/Leveraged		Market Cap		SMA50	-4.76%	Flows% 5Y		Avg Volume	2.52K	Price	23.59
IPO	May 21, 2024	Option/Short	No / Yes	SMA200	-3.46%	Trades		Volume	564	Change	-1.34%

Feb-04-26 09:30AM	Healthcare ETFs to Watch as Novo Nordisk Tumbles on Poor Sales Outlook (Zacks)
Dec-29-25 08:46AM	The Obesity Pill Rush: Healthcare ETFs to Gain as FDA Nods to Novo Drug (Zacks)
Nov-24-25 07:00AM	Eli Lilly Hits $1 Trillion Milestone: ETFs to Invest in (Zacks)
Aug-19-25 06:15AM	NVO Wins FDA Approval for MASH Treatment: ETFs Likely to Gain (Zacks)
Jun-11-25 06:05AM	Weight-Loss Drug ETFs Generate Skinnier Returns Than Expected (The Daily Upside)
07:12AM	Loading…
Jun-02-25 07:12AM	Weight Loss Drug ETF (THNR) Hits New 52-Week High (Zacks)
May-15-25 10:00AM	ETFs to Capitalize on the Novo Nordisk-Septerna Deal (Zacks)
Jan-16-25 07:00AM	Amplify ETFs Achieves Landmark $10 Billion in Assets Under Management (GlobeNewswire)
Sep-04-24 12:26PM	3 ETFs to stabilize a portfolio amid volatility: Amplify CEO (Yahoo Finance Video)
Jun-05-24 07:00AM	Amplify ETFs Earns Four Nominations for With Intelligence Mutual Fund and ETF Awards (GlobeNewswire)
May-21-24 07:00AM	Amplify ETFs Launches The Amplify Weight Loss Drug & Treatment ETF (THNR) (GlobeNewswire)

Amplify Weight Loss Drug & Treatment ETF seeks investment results that generally correspond to the performance (before fees and expenses) of the VettaFi Weight Loss Drug & Treatment Index. The fund's manager invests at least 80% of its net assets (plus borrowings for investment purposes) in securities that comprise the index. The index is comprised of global companies who are manufacturers in the GLP-1 agonist pharmaceutical business or who enable such business. GLP-1 agonists (glucagon-like peptide) seek to lower blood sugar levels and reduce appetite and promote fullness, with the ultimate potential for weight loss. The fund is non-diversified.

open in yahoo | open in marketwatch | open in google

THNR

Amplify Weight Loss Drug & Treatment ETF

Upgrade your Finviz experience